Signatures of divergent antimalarial treatment responses in peripheral blood from infants and adults in Malawi in order to isolate age-specific effects on UM, and also to avoid exacerbation of disease among participants, we collected and stored at -80°C. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque 64 gradient separation and then frozen in 10% DMSO / 90% fetal bovine serum (FBS) and stored in liquid nitrogen.
Plasma cytokines
For all additional blood analyte phenotypes that were measured at both V1 and V2, we modeled our data transmitted to a new female mosquito during bloodfeeding. Whereas it is blood stage parasites that primarily drive clinical disease, gameotocytes are important for human-to-mosquito transmission.
males, 1 female). Only two subjects, both infants (1 male, 1 female), transitioned from no detectable antimalarial 186 antibody at V1 to detectable antibody at V2 (Supplemental Figure S2 , Supplemental Table S1 ).
Nitric oxide

188
Nitric oxide (NO) is a molecular effector that is released by activated immune cells in their defense against 189 parasite infection [38] . Increased plasma NO levels in adults and children have been associated with protection 190 from malaria [39, 40, 41] . In order to determine whether age, sex, or treatment significantly affected NO levels 191 in our population, we measured NO levels in plasma. We detected significant age-dependent effects on NO levels
192
(p = 1.191 × 10 −10 ). However, we did not detect significant overall effects of treatment on NO concentrations.
193
No significant sex-specific effect on NO was observed, although the variation in NO at both time points was 194 substantially higher in infant females (sd V1 = 121.159, sd V2 = 82.213) than in infant males (sd V1 = 47.508, 195 sd V2 = 49.970) (Figure 3 ).
196
Plasma cytokines
197
To characterize the host immunological response to malaria infection and antimalarial treatment, we measured 198 cytokine protein levels using a MILLIPLEX panel of nine analytes (TNF-α, IFN-γ, IL-6, IL-12 (p40), (p70), IL-10, GM-CSF, sCD40L, and IL-1β). To model our data, we used a nonparametric, rank-based statistical sex:visit, age:sex:visit) on plasma cytokine levels in our population. We summarize our results below ( Figure   203 3, Supplmental Table S2 ).
204
Pro-inflammatory cytokines 205 We found a small, but highly significant, overall effect of visit on TNF-α levels (p = 1.282 × 10 −7 ), where infants only, with higher IL-12(p40) levels after treatment. This manifested as a marginal age:sex:treat effect (p = 3.475 × 10 −2 ).
220
Observed levels of IL-1β were often below detectable limit, and the levels of sCD40L were often above the 221 detectable range, making their quantification highly uncertain, and leading us to exclude those cytokine mea-
222
surements from our analysis.
223
Anti-inflammatory cytokine and growth factor 224 We observed a significant effect of visit (treatment) on plasma levels of IL-10 (p = 2.566 × 10 −15 ), where post-225 treatment levels were substantially lower than during acute infection. We also observed a significant effect of 226 age on IL-10, where infants had significantly higher levels than adults at both time points (p = 3.305 × 10 −7 ).
227
We observed a small but significant effect of treatment on levels of GM-CSF in the plasma (p = 1.151 × 10 −3 ),
228
where post-treatment individuals had slightly elevated GM-CSF, regardless of age group. Males trended toward
229
higher mean values across the two time points and ages.
230
Treatment failure
231
Although we did not expect a priori for there to be antimalarial treatment failures in our cohort, we found 232 that five individuals remained parasitaemic even after treatment, likely indicating treatment failure and/or 233 reinfection by V2 (Supplemental Figure S3) . Among the five, parasite levels were reduced by only ∼5% 234 in a single female infant, and by >97% in the remaining 4 individuals. All five individuals had lower plasma on treatment response that we observed were for IFN-γ / IL-12(p70) (p = 8.849 × 10 −4 ) and IFN-γ / GM-CSF
249
(p = 9.116 × 10 −4 ). visit/treatment, however we observed an overall trend for higher percentages in the second visit than during the 255 first, and for higher levels in adults than infants ( Figure 5A ). We found that the proportion of myeloid dendritic 256 cells (mDCs) among all PMBCs, while very small (often < 0.1%), was significantly higher post-treatment than
257
during acute infection in all groups (p = 6.032 × 10 −8 ). In addition, nearly significant effects were observed for 258 age (p = 4.665 × 10 −2 ) and an age:visit interactions (p = 4.282 × 10 −2 ), mostly due to lower mDC levels in 259 infants vs. adults during the acute visit (similar levels of post-treatment mDCs) ( Figure 5B ).
260
Traditional, classical and patrolling monocytes serve different roles in pathogen surveillance, effector functions,
261
and disease pathogenesis [42] . We observed a significant treatment effect on patrolling monocytes (p = 1.168
where levels increased significantly post-treatment in both infant and adult populations ( Figure 5C ). Although 263 not significant, it appeared that age changed the direction of the treatment response for both inflammatory
264
( Figure 5D ) and traditional monocytes ( Figure 5E ). We observed a significant effect of treatment on the 265 frequency of CD14 low monocytes (p = 1.648 × 10 −2 ) as a percentage of the total CD16 -monocytes ( Figure   266 5F).
267
A summary of p-values for age, sex, visit, and interaction effects for all analyte, analyte ratio, and cellular
268
p-values is included in Figure 6 .
269
Within-group age-dependent effects on analyte levels
270
Additional blood analyte heterogeneity within-group, adult or infant, may be caused by age-dependent effects 271 that are not captured by the binary coding of age used in our main analysis. To identify continuous rather than 272 categorical age effects, we used a linear model, fitting age (in years for adults, or fraction of years for infants)
273
and age-by-sex effects for adults and infants separately, at each treatment timepoint, and fitting the same effects 274 for the log 2 -fold change between acute and post-treatment visits. Although we found no significant effects on 275 the treatment response (log 2 -fold change), we identified significant within-group age effects at both visit 1 and 276 visit 2.
277
At visit 1, we found significant within-group age effects on infant TNF-α (ANOVA-like p = 0.008, decrease
278
with age, appears to be driven by females) ( Figure 7A) , and on adult GM-CSF (p = 0.032, increase with age), adult IL-12(p70) (p = 0.0475, slight decrease with age, not shown), and adult Pfs16 (p = 0.00976, decrease with 280 age), including substantial effects of age (p = 0.0032) and age-by-sex interaction (p = 0.0027) ( Figure 7B ).
281
At visit 2, we found significant within-group age effects on adult nitric oxide (p = 0.014, increase with age),
282
including substantial effects of age (p = 0.017) and age-by-sex interaction (p = 0.0093) ( Figure 7C ). antibody.
320
The role of nitric oxide (NO) in malaria is still controversial. Even as higher levels of NO are associated with
321
CM and dyserythropoiesis, some studies have found that NO levels are often higher in asymptomatic children.
322
Our results suggest that NO levels are upregulated in infants compared with adults, however these measures 323 did not change between V1 and V2, and they did not correlate with parasitemia as other studies have found
324
[45]. This may reflect our power to detect such effects given the size of our sample, or differences in regional or 325 environmental factors contributing to NO levels in the blood.
326
One limitation of our current study is that we lacked clinical outcomes beyond a simple measure of parasitemia,
327
limiting our ability to understand the impact of our blood phenotyping results on adverse outcomes; we excluded 328 individuals with signs of SMA or CM, so the clinical variation in this study is by design very low. Even so, we 329 were able to identify specific signatures of infant age that are associated with changes in the host antimalarial for infants, (B) Pfs16 levels at V1 for adults, and (C) NO levels at V2 for adults. Age is presented in years. In order to properly transform our data prior to using a linear mixed model, we first handled heteroskedasticity 554 of the residuals using a power transform based on a Box-Cox analysis. We start by fitting our data using a linear 555 model: 556 y raw = β age + β sex + β visit + β age:sex + β age:visit + β sex:visit + β age:sex:visit + ε
where the values for ε are i.i.d. normal. We then use this fit to determine the value of λ with the maximum 557 log likelihood, where λ represents the exponent and divisor in the follwing data transform:
where log is the natural log, according to [53] , implemented in the R package MASS [31]. After finding approxi-
559
mate optimal values of lambda, the transforms used for each phenotypes are as follows, where fractions represent 560 the values of lambda used, "none" represents no transformation, and "log" is the natural log transformation: 561 analyte: GM-CSF IFN-γ IL-10 IL-12(p40) IL-12(p70) IL-6 TNF-α hemoglobin nitric oxide transform:
near the upper detection limit for this cytokine, which may have reduced our ability to detect differences 571 based on treatment, age, and sex. We found that IL-1β levels in plasma increased significantly after treatment
572
(p = 9.162 × 10 −4 ), and we found no other significant effects. This cytokine was at the lower limit of detection,
573
which may have also reduced our ability to detect significant effects.
574
Linear mixed model analysis of analytes
575
We expect subtle differences in our main results based on the model that is selected. To determine whether 576 our findings are sensitive to model type and specification, we applied a linear mixed model in addition to the 577 nonparametric model reported in the main results. We found that the majority (9 of 16) of the significant 578 effects identified by our nonparametric model, presented in Figure 6 , were also found using a LMM, as described 579 above (Supplemental Table S4 ). Using ANOVA on the LMM (using the package lmerTest), we uncovered 580 an additional 3 significant effects for IL-6 (sex, p = 0.041) and IL-10 (age, p = 0.0096; age-by-sex, p = 0.020)
581
[55]. 
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